A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants

NCT02440035 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

BIOLOGICAL: Ad35.RSV.FA2
BIOLOGICAL: Ad26.RSV.FA2
DRUG: Placebo

Sponsor

Crucell Holland BV